Tanya Hundal

This paper develops a PD-1 chimeric switch receptor T-cell platform that improves tumor targeting while reducing toxicity to normal cells in PD-L1-targeted therapies.

This study develops a PD-L1-targeting CAR T cell therapy, MC9999, which effectively eradicates glioblastoma and immunosuppressive cells in the tumor microenvironment through intracranial delivery.

This paper develops a PD-L1-targeting CAR T-cell therapy (MC9999) that effectively attacks both tumor and immunosuppressive cells in solid tumors.